Development of New Geographic Atrophy in Patients With Neovascular (Wet) Age-related Macular Degeneration: a Comparison of Ranibizumab and Aflibercept

Trial Profile

Development of New Geographic Atrophy in Patients With Neovascular (Wet) Age-related Macular Degeneration: a Comparison of Ranibizumab and Aflibercept

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
  • Indications Dry macular degeneration; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms RIVAL
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jan 2015 Planned End Date changed from 1 Dec 2017 to 1 Oct 2017 according to ClinicalTrials.gov record.
    • 07 Jan 2015 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2017 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top